keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/29470778/guselkumab-for-the-treatment-of-psoriasis
#1
REVIEW
Álvaro Machado, Tiago Torres
Psoriasis is a common, chronic, immune-mediated, inflammatory skin disease with systemic involvement and significant impact on patients' quality of life. Several biologic treatments have been developed in recent decades, such as tumor necrosis factor (TNF)-α inhibitors, a non-selective interleukin (IL)-23 inhibitor (ustekinumab, which also inhibits IL-12), and-most recently-IL-17 inhibitors. Guselkumab is a novel biological therapy that selectively targets IL-23 and is the first-in-class selective IL-23 inhibitor approved to treat moderate-to-severe plaque psoriasis...
February 22, 2018: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29469799/complete-response-of-secukinumab-in-palmoplantar-psoriasis
#2
Vicenç Rocamora, Joan Garcías-Ladaria
Palmoplantar psoriasis is plaque psoriasis involving the palms and soles. Palmoplantar psoriasis is a treatment challenge for dermatologists and it is difficult to treat with topical and systemic therapies. Owing to its location and manifestations, palmoplantar psoriasis is associated with greater pain, functional limitations, and significant impairment of health-related quality of life. Recently a new biologic agent, secukinumab, has been approved for treatment of moderate to severe plaque psoriasis. GESTURE trial is a study of the secukinumab clinical development that evaluates efficacy and safety in this subpopulation of patients...
October 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/29462231/efficacy-and-safety-of-apremilast-in-systemic-and-biologic-naive-patients-with-moderate-plaque-psoriasis-52-week-results-of-unveil
#3
Linda Stein Gold, Jerry Bagel, Mark Lebwohl, J Mark Jackson, Rongdean Chen, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin
<p>BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in systemic-naive patients with chronic moderate plaque psoriasis with lower psoriasis-involved body surface area (BSA; 5%-10%) during the 16-week, double-blind, placebo-controlled phase. We describe efficacy and safety of apremilast in this population through week 52 in UNVEIL.</p> <p>METHODS: Patients with moderate plaque psoriasis (BSA 5%-10%; static Physician's Global Assessment [sPGA] score of 3 [moderate]) and naive to systemic therapies for psoriasis were randomized (2:1) to receive apremilast 30 mg twice daily or placebo for 16 weeks...
February 1, 2018: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29455895/childhood-trauma-and-resilience-in-psoriatic-patients-a-preliminary-report
#4
Maria Luigia Crosta, Clara De Simone, Salvatore Di Pietro, Mariateresa Acanfora, Giacomo Caldarola, Lorenzo Moccia, Antonino Callea, Isabella Panaccione, Ketty Peris, Lucio Rinaldi, Luigi Janiri, Marco Di Nicola
AIMS: Psoriasis is a chronic inflammatory skin disease with a complex etiology, involving the immune system, genetic factors, and external/internal triggers, with psychosomatic aspects. The aim of the study was to investigate childhood trauma and resilience in a psoriatic sample compared with healthy controls. Correlations between childhood trauma, resilience, quality of life, clinical data and psoriatic features were also evaluated. METHODS: Seventy-seven psoriatic patients and seventy-six homogeneous healthy controls were enrolled...
March 2018: Journal of Psychosomatic Research
https://www.readbyqxmd.com/read/29453712/author-correction-to-psoriasis-in-skin-of-color-insights-into-the-epidemiology-clinical-presentation-genetics-quality-of-life-impact-and-treatment-of-psoriasis-in-non-white-racial-ethnic-groups
#5
Bridget P Kaufman, Andrew F Alexis
In the original publication, section 5, paragraph 1 was incorrectly published.
February 16, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29444376/secukinumab-demonstrates-high-sustained-efficacy-and-a-favorable-safety-profile-in-patients-with-moderate-to-severe-psoriasis-through-5-years-of-treatment-sculpture-extension-study
#6
R Bissonnette, T Luger, D Thaçi, D Toth, A Lacombe, S Xia, R Mazur, M Patekar, P Charef, M Milutinovic, C Leonardi, U Mrowietz
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favorable safety profile in the treatment of moderate to severe psoriasis and psoriatic arthritis. OBJECTIVE: To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate to severe psoriasis. METHODS: In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1...
February 14, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29441473/cost-and-cost-effectiveness-of-treatments-for-psoriatic-arthritis-a-systematic-literature-review
#7
REVIEW
Lucia Sara D'Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giancarlo Cesana, Lorenzo Giovanni Mantovani
BACKGROUND: Psoriatic arthritis is a long-term inflammatory arthropathy occurring in a subgroup of patients with psoriasis. In addition to irreversible bone erosions, joint destruction, and skin manifestations, psoriatic arthritis is associated with numerous comorbid conditions. Over the last 5 years, new treatments emerged; the analysis and comparisons of their additional costs and the added benefits have become increasingly important to optimize the limited resources available. METHODS: A systematic literature review covering PubMed, EMBASE, and the Cochrane Library was performed from May 2012 to October 2017 focusing on the most recent evidence of costs, benefits, and burden of psoriatic arthritis and its treatments...
February 13, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29441294/effect-of-an-educational-and-psychological-intervention-on-knowledge-and-quality-of-life-among-patients-with-psoriasis
#8
Padmavathi Nagarajan, Devinder Mohan Thappa
Background: Psoriasis is one of the most common skin disorders with a prevalence rate of 0.1%-3%. Chronic nature, frequent relapses, absence of permanent cure, and the cosmetic disfigurement of psoriasis have a negative impact on quality of life (QoL) by causing psychological stress. Patients with psoriasis often have unambiguous ideas about the causes, controllability, consequences, and expected time-course of their disease. Aim: The aim of this study is to assess the effectiveness of a video-assisted teaching program regarding psoriasis on the level of knowledge and relaxation therapy on QoL among patients with psoriasis...
January 2018: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/29439003/impact-of-red-and-processed-meat-and-fibre-intake-on-treatment-outcomes-among-patients-with-chronic-inflammatory-diseases-protocol-for-a-prospective-cohort-study-of-prognostic-factors-and-personalised-medicine
#9
Robin Christensen, Berit L Heitmann, Karina Winther Andersen, Ole Haagen Nielsen, Signe Bek Sørensen, Mohamad Jawhara, Anette Bygum, Lone Hvid, Jakob Grauslund, Jimmi Wied, Henning Glerup, Ulrich Fredberg, Jan Alexander Villadsen, Søren Geill Kjær, Jan Fallingborg, Seyed A G R Moghadd, Torben Knudsen, Jacob Brodersen, Jesper Frøjk, Jens Frederik Dahlerup, Anders Bo Bojesen, Grith Lykke Sorensen, Steffen Thiel, Nils J Færgeman, Ivan Brandslund, Tue Bjerg Bennike, Allan Stensballe, Erik Berg Schmidt, Andre Franke, David Ellinghaus, Philip Rosenstiel, Jeroen Raes, Mette Boye, Lars Werner, Charlotte Lindgaard Nielsen, Heidi Lausten Munk, Anders Bathum Nexøe, Torkell Ellingsen, Uffe Holmskov, Jens Kjeldsen, Vibeke Andersen
INTRODUCTION: Chronic inflammatory diseases (CIDs) are frequently treated with biological medications, specifically tumour necrosis factor inhibitors (TNFi)). These medications inhibit the pro-inflammatory molecule TNF alpha, which has been strongly implicated in the aetiology of these diseases. Up to one-third of patients do not, however, respond to biologics, and lifestyle factors are assumed to affect treatment outcomes. Little is known about the effects of dietary lifestyle as a prognostic factor that may enable personalised medicine...
February 8, 2018: BMJ Open
https://www.readbyqxmd.com/read/29430733/the-relationship-between-clinical-characteristics-including-presence-of-exposed-lesions-and-health-related-quality-of-life-hrqol-in-patients-with-psoriasis-analysis-from-the-nationwide-epidemiologic-study-for-psoriasis-in-korea-epi-psode-study
#10
S W Youn, J-H Lee, D Y Yu, Y Kim, B S Kim, S J Seo, Y B Choe, S-K Yun, J Park, N I Kim, C W Choi, J I Youn, S-J Lee, M-G Lee, K J Kim, C J Park, Y S Ro, H J Song, B S Shin, S K Ahn, J Y Lee, Y H Won, M S Jang, K H Kim, M H Kim, T Y Kim, J H Choi
BACKGROUND: Psychological aspect and quality of life should be considered in treating patients with psoriasis. OBJECTIVE: We sought to ascertain which clinical characteristics including presence of exposed lesions are associated with impairment of health-related quality of life (HRQoL) in patients with psoriasis. METHODS: The EPI-PSODE study was a nationwide, multicenter, cross-sectional study conducted in Korea that included 1,260 adult patients with psoriasis...
February 11, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29424306/biologic-therapy-in-psoriasis-part-i-efficacy-and-safety-of-tumor-necrosis-factor-%C3%AE-inhibitors
#11
A Campanati, E Molinelli, G Ganzetti, V Brisigotti, A Offidani
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety profile extensively examined and monitored. METHODS: Biological therapies currently available can be divided into three main categories: the TNFα antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab)...
February 9, 2018: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29415699/can-an-app-supporting-psoriasis-patients-improve-adherence-to-topical-treatment-a-single-blind-randomized-controlled-trial
#12
Mathias Tiedemann Svendsen, Flemming Andersen, Kirsten Hammond Andersen, Klaus Ejner Andersen
BACKGROUND: Topical corticosteroid or corticosteroid/calcipotriol preparations are recommended first-line topical treatments of psoriasis, but a main cause for the lack of efficacy of topical treatments is considered low rates of adherence to topical drugs. Patient support by the use of applications (apps) for smartphones is suggested to improve medical adherence. METHODS/DESIGN: Design: An investigator-initiated, single-center, single-blind, parallel-group, phase-4 clinical superiority randomized controlled trial (RCT)...
February 7, 2018: BMC Dermatology
https://www.readbyqxmd.com/read/29404966/efficacy-and-safety-of-secukinumab-in-elderly-subjects-with-moderate-to-severe-plaque-psoriasis-a-pooled-analysis-of-phase-iii-studies
#13
Andreas Körber, Charis Papavassilis, Vaishali Bhosekar, Maximilian Reinhardt
BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis. AIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects...
February 5, 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29399784/subcutaneous-methotrexate-in-patients-with-moderate-to-severe-psoriasis-a-critical-appraisal
#14
T Tsakok, Z K Jabbar-Lopez, C H Smith
AIM: Warren et al1 set out to assess the effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe chronic plaque psoriasis. SETTING AND DESIGN: This is a prospective, double-blind, randomised (3:1), placebo-controlled study, conducted across 16 centres in Germany, France, the Netherlands, and the UK. STUDY EXPOSURE: Methotrexate-naïve adults with a diagnosis of moderate to severe chronic plaque psoriasis for at least 6 months before baseline were randomly assigned to receive weekly subcutaneous injections of either methotrexate at a starting dose of 17...
February 5, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29399255/treatment-satisfaction-product-perception-and-quality-of-life-in-plaque-psoriasis-patients-using-betamethasone-dipropionate-spray-0-05
#15
Joseph F Fowler, James Q Del Rosso, Refika I Pakunlu, Srinivas Sidgiddi
Objective: To assess patient-reported satisfaction, efficacy, and tolerability associated with the use of betamethasone dipropionate spray 0.05% when applied twice daily in subjects with moderate plaque psoriasis. Design: This was an open-label, multicenter study involving 45 patients with moderate plaque psoriasis, with the aim of evaluating patient-reported outcomes with betamethasone dipropionate spray 0.05%. Patients treated all affected areas twice daily with betamethasone dipropionate (BD) spray 0.05% for 28 days per label instructions...
November 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29395573/increased-levels-of-lipocalin-2-in-palmoplantar-pustular-psoriasis
#16
Kerstin Wolk, Yvonne Frambach, Arnd Jacobi, Dagmar Wilsmann-Theis, Sandra Phillipp, Ellen Witte-Händel, Jörg Wenzel, Rotraut Mössner, Robert Sabat
BACKGROUND: Palmoplantar pustular psoriasis (PPP) is a recalcitrant chronic skin disease affecting the palms and soles. OBJECTIVE: To identify and characterize pathogenetic players in PPP. METHODS: Clinical and anamnestic data as well as skin and blood samples of 60 PPP patients were collected. Healthy participants served as controls. Analysis of patient samples and cultured primary skin cells was performed by ELISA, qRT-PCR, and immunohistochemistry...
January 11, 2018: Journal of Dermatological Science
https://www.readbyqxmd.com/read/29388335/real-world-data-on-the-efficacy-and-safety-of-apremilast-in-patients-with-moderate-to-severe-plaque-psoriasis
#17
E Papadavid, N Rompoti, K Theodoropoulos, G Kokkalis, D Rigopoulos
BACKGROUND: Psoriasis is a chronic inflammatory skin disease, which requires long term, safe and effective treatment. Apremilast, a small-molecule PDE4 inhibitor, has been introduced as psoriasis (and psoriatic arthritis) treatment in Europe in 2015. OBJECTIVE: We analysed and report the efficacy and safety of apremilast in the first 51 patients with psoriasis that have undergone treatment with this novel small molecule in our outpatient clinic. METHOD: Our primary endpoint was the evaluation of clinical response to apremilast according to the percentage of PASI reduction (ΔPASI) at 16 weeks after treatment initiation...
February 1, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29368846/cyclosporine-in-clinical-practice-a-retrospective-study-comparing-fixed-dose-and-body-weight-based-dose-regimens-in-psoriatic-patients
#18
Federico Bardazzi, Giulia Odorici, Michela Magnano, Annalisa Patrizi, Vera Tengattini
BACKGROUND: In the treatment of various diseases, such as diabetes and arterial hypertension, fixed dose therapies have been reported to offer a method to simplify complex treatment regimens. There are numerous clinical trials proving the efficacy of cyclosporine in psoriasis in inducing remission and maintaining results, although there are few studies about the treatment optimization of cyclosporine. METHODS: We performed a 15-year retrospective observational study comparing two groups of psoriatic patients matched for age and sex...
January 24, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29364458/nail-psoriasis-treated-with-pulsed-dye-laser
#19
Juliano Peruzzo, Gabriela Czarnobay Garbin, Gabriela Maldonado, Tania Ferreira Cestari
Nail changes are present in about 50% of psoriasis patients and tend to be refractory to conventional treatments. Pulsed dye laser has emerged as an alternative therapy. Our aim is to evaluate the efficacy of pulsed dye laser in nail psoriasis and the impact of treatment on quality of life. Fourteen patients were treated in monthly sessions for three months. The outcome assesment was made by the Nail Psoriasis Severity Index (NAPSI). The median improvement in the scores of the overall NAPSI, nail bed NAPSI, and nail matrix NAPSI were 44...
November 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/29363093/a-prospective-52-week-randomised-controlled-trial-of-patient-initiated-care-consultations-for-patients-with-psoriasis
#20
L R Khoury, T Møller, C Zachariae, L Skov
BACKGROUND: Treatment and care of moderate to severe psoriasis requires lifelong consultations with a dermatologist with close monitoring of systemic treatment. OBJECTIVES: To investigate the effect of patient-initiated care consultations (PICC) for patients with psoriasis in a dermatology outpatient clinic. METHODS: A prospective randomised controlled trial with patients in well-controlled systemic treatment randomised to either 1) the PICC group, where they participated in one annual consultation with a dermatologist but were able to initiate consultations when needed; or 2) routine care, where they participated in a consultation every 12-16 weeks...
January 24, 2018: British Journal of Dermatology
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"